Display options
Cite
Yuen JW, Gohel MD, Ng CF. Synergistic Cytotoxic Effects of Ganoderma lucidum and Bacillus Calmette Guérin on Premalignant Urothelial HUC-PC Cells and Its Regulation on Proinflammatory Cytokine Secretion. Evid Based Complement Alternat Med. 2012;2012:147896doi: 10.1155/2012/147896.
Yuen, J. W., Gohel, M. D., & Ng, C. F. (2012). Synergistic Cytotoxic Effects of Ganoderma lucidum and Bacillus Calmette Guérin on Premalignant Urothelial HUC-PC Cells and Its Regulation on Proinflammatory Cytokine Secretion. Evidence-based complementary and alternative medicine : eCAM, 2012147896. https://doi.org/10.1155/2012/147896
Yuen, John Wai-Man, et al. "Synergistic Cytotoxic Effects of Ganoderma lucidum and Bacillus Calmette Guérin on Premalignant Urothelial HUC-PC Cells and Its Regulation on Proinflammatory Cytokine Secretion." Evidence-based complementary and alternative medicine : eCAM vol. 2012 (2012): 147896. doi: https://doi.org/10.1155/2012/147896
Yuen JW, Gohel MD, Ng CF. Synergistic Cytotoxic Effects of Ganoderma lucidum and Bacillus Calmette Guérin on Premalignant Urothelial HUC-PC Cells and Its Regulation on Proinflammatory Cytokine Secretion. Evid Based Complement Alternat Med. 2012;2012:147896. doi: 10.1155/2012/147896. Epub 2012 Aug 28. PMID: 22969822; PMCID: PMC3434421.
Copy Download .nbib Format: NLM
Share it on

Evid Based Complement Alternat Med. 2012;2012:147896. doi: 10.1155/2012/147896. Epub 2012 Aug 28.

Synergistic Cytotoxic Effects of Ganoderma lucidum and Bacillus Calmette Guérin on Premalignant Urothelial HUC-PC Cells and Its Regulation on Proinflammatory Cytokine Secretion.

Evidence-based complementary and alternative medicine : eCAM

John Wai-Man Yuen, Mayur-Danny I Gohel, Chi-Fai Ng

Affiliations

  1. School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Hong Kong.

PMID: 22969822 PMCID: PMC3434421 DOI: 10.1155/2012/147896

Abstract

Bacillus Calmette-Guérin (BCG) is conventionally used as an adjuvant immunotherapy to reduce the recurrence of bladder cancer. To address the issues of efficacy and safety, an ethanol extract of Ganoderma lucidum (GLe) was evaluated for its interaction with BCG. In a model of premalignant human uroepithelial cells (HUC-PC), GLe exerted immediate cytotoxic effects while BCG showed a delayed response, given that both were immunological active in inducing the secretion of interleukin (IL)-6, IL-8, and monocyte chemotactic protein-1 (MCP-1). Synergistic cytotoxic effects were observed when cells were either coincubated with both drugs or firstly preincubated with GLe. Synergism between GLe and BCG was demonstrated to achieve a complete cytostasis in 24 hours, and such effects were progressed in the subsequent 5 days. However, the pretreatment of GLe resulted in suppression of IL-6, IL-8, and MCP-1 secretions without affecting the cytotoxicity. Given that numerous proinflammatory cytokines are associated with the high side effects toll of BCG, results herein suggested the potential implications of GL to supplement the BCG immunotherapy in bladder cancer, for better efficacy and reducing side effects.

References

  1. BJU Int. 2010 Apr;105(7):1011-5 - PubMed
  2. Cancer Res. 2001 Jan 1;61(1):355-62 - PubMed
  3. Cancer Lett. 2004 Dec 8;216(1):9-20 - PubMed
  4. Urol Res. 1998;26(3):155-9 - PubMed
  5. J Urol. 2001 Oct;166(4):1300-4, discussion 1304-5 - PubMed
  6. Clin Cancer Res. 2004 Dec 1;10(23):7994-8004 - PubMed
  7. Biosci Biotechnol Biochem. 2006 Sep;70(9):2028-34 - PubMed
  8. Cytokine. 2003 Jan 7;21(1):17-26 - PubMed
  9. Evid Based Complement Alternat Med. 2012;2012:809614 - PubMed
  10. J Ethnopharmacol. 2008 Jul 23;118(2):324-30 - PubMed
  11. Br J Urol. 1998 Jul;82(1):118-21 - PubMed
  12. Urol Int. 2005;75(1):80-7 - PubMed
  13. Bioorg Med Chem. 2004 Nov 1;12(21):5595-601 - PubMed
  14. Eur Urol. 2003 Oct;44(4):423-8 - PubMed
  15. Br J Cancer. 1999 Jan;79(2):229-35 - PubMed
  16. Nutr Cancer. 2008;60(1):109-19 - PubMed
  17. Cancer Immunol Immunother. 2002 Apr;51(2):91-8 - PubMed
  18. Nutr Cancer. 2005;53(1):11-7 - PubMed
  19. Cancer Immunol Immunother. 1992;34(5):306-12 - PubMed
  20. Urol Oncol. 2012 Sep;30(5):652-9 - PubMed
  21. Urol Int. 1997;59(3):142-8 - PubMed
  22. Cancer Lett. 2005 Mar 18;220(1):21-8 - PubMed
  23. Aust N Z J Surg. 1998 May;68(5):340-4 - PubMed
  24. World J Urol. 2009 Jun;27(3):343-6 - PubMed
  25. Cancer Res. 1992 Mar 15;52(6):1606-14 - PubMed
  26. J Ethnopharmacol. 2011 Jun 1;135(3):711-8 - PubMed
  27. Cancer Res. 2004 May 15;64(10):3386-90 - PubMed
  28. Expert Rev Anticancer Ther. 2003 Dec;3(6):793-8 - PubMed
  29. BJU Int. 2006 Apr;97(4):860-4 - PubMed
  30. J Biosci Bioeng. 2001;92(6):550-5 - PubMed
  31. Blood. 2005 Nov 15;106(10):3474-82 - PubMed
  32. Urology. 2006 Oct;68(4):702-6 - PubMed
  33. Int J Urol. 2006 Nov;13(11):1389-92 - PubMed
  34. Genes Dev. 2009 Mar 1;23(5):537-48 - PubMed
  35. Int J Cancer. 1997 May 29;71(5):851-7 - PubMed
  36. Br J Cancer. 2004 Aug 16;91(4):607-12 - PubMed

Publication Types